Business
Inspira™ Granted U.S. Patent for INSPIRA™ ART500 Medical Device
This new patent advances Inspira's ability to enter into the Company estimated $20 billion market as a potential innovative frontrunner with planned global
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"This new patent advances Inspira's ability to enter into the Company estimated $20 billion market as a potential innovative frontrunner with planned global deployments of its exclusive INSPIRA ART500 and disruptive technology.\nRA'ANANA, Israel, Oct. 25, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (the \"Company\" or \"Inspira \"), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, announced today the grant of an additional patent by the U.S. Patent and Trademark Office for its respiratory medical device, the INSPIRATM ART500.\n\n \n \nThe newly granted patent relates to a novel automated self-priming module designed for the INSPIRA ART500 device. This unique innovative operating module further expands the INSPIRA ART500 advancement to potentially ensure patient safety with a proprietary built-in self-automated priming module aimed to ensure an emboli-free connection to the patient's vascular system, thereby potentially reducing risks of the formation of clots that reduces blood flow. The patent consists of nine distinct claims, all deemed novel with inventive merit and practical applicability. In addition to the United States, the Company has initiated patent applications in Europe and several countries in other regions. \nIn a market that serves approximately 20 million patients every year who are treated by mechanical ventilation systems and may suffer from the associated risks and medical complications, the INSPIRA ART500 potentially brings hope for change by aiming to reduce the need for mechanical ventilation systems that are associated with a sliding 50% mortality rate, may heighten the risk of coma, and may cause bacterial infections and associated mechanical ventilation lung injuries.\nInspira's CEO, Dagi Ben-Noon, commented: \"We believe that this patent approval represents a further recognition of our unique solution alongside a major milestone towards the INSPIRATM ART500 system and building a global medical solution. We are working diligently to convert our innovation into value for our shareholders.\"\nAbout Inspira Technologies OXY BHN Ltd. \nInspira Technologies maintains a steadfast mission to revolutionize acute respiratory care through innovation. The Company's primary objective is the development of medical technologies and products a...